Currently, there are two common types of PLK1 inhibitors: ATP-competitors (targeting KD) and non-ATP competitors (targeting PBD), both of which have entered clinical trials in hematologic malignancies and solid tumors because of their promising antitumor effects of PLK1 in pre-clinical models of cancer (Figure 1; Table 3). Here, PLK1 is linked to cancer.